GAIN Act Update: Antibiotic Pipeline Problem is Politically Ripe
This article was originally published in RPM Report
Executive Summary
As the PDUFA reauthorization process approaches, antibiotic drug development is poised as an area to see some legislative action. A recent workshop highlighted the interest in such action and evidence it may be effective.
You may also be interested in...
GAIN Is Great: Now Who Gets the Benefits?
Congress is set on enacting a package of antibiotic development incentives—but needs to sort out how best to define the targets.
Antibiotic Incentive Bill Reintroduced: Industry Hopes for 2012 Enactment
The bill focuses on particularly virulent, resistant pathogens and also includes priority review designations and review of FDA guidelines.
Antibiotic Early Endpoints: FDA Looking At Patient Observations
An effort to identify early biomarkers of antibiotic efficacy is turning toward patient assessments of drug activity. FDA and industry scientists are both participating in the biomarker effort. The attention to patient observations reflects a growing interest at FDA.